-
A Phase 2 Open Label Study of BA3021 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Not Recruiting
More
This is a multi-center, open-label Phase 2 study designed to evaluate the efficacy and safety
of BA3021 in PD-1/L1 failure patients with ROR-2 expression in recurrent or metastatic
squamous cell carcinoma of the head and neck.
Stanford is currently not accepting patients for this trial.
For more information, please contact Cancer Clinical Trials Office (CCTO), 650-498-7061.
Stanford Investigators
View full details
-
INCAGN01876 in Combination With Immunotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Not Recruiting
More
The purpose of this study is to determine the safety, tolerability, efficacy, PK and
pharmacodynamics of INCAGN01876 when given in combination with retifanlimab. The study will
consist of 2 parts: a safety lead-in part (Part 1) followed by a dose expansion part (Part
2).
Stanford is currently not accepting patients for this trial.
For more information, please contact Cancer Clinical Trials Office (CCTO), 650-498-7061.
Stanford Investigators
View full details
-
A Multicenter Cancer Biospecimen Collection Study
Recruiting
More
This study will collect de-identified tumor samples, with correlated clinical/demographic
data and tissue histology, from patients selected or scheduled for pre-treatment tumor biopsy
or who have had a recent pre-treatment tumor biopsy. These specimens and clinical data may be
used in subsequent studies for the development and validation of a diagnostic test.
Stanford Investigators
View full details
-
Testing the Addition of an Anti-cancer Drug, Ipatasertib, to the Usual Immunotherapy Treatment (Pembrolizumab) in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck
Recruiting
More
This phase II trial compares the effect of adding ipatasertib to pembrolizumab (standard
immunotherapy) vs. pembrolizumab alone in treating patients with squamous cell cancer of the
head and neck that has come back (recurrent) or that has spread from where it first started
(primary site) to other places in the body (metastatic). Ipatasertib is in a class of
medications called protein kinase B (AKT) inhibitors. It may stop the growth of tumor cells
and may kill them. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help
the body's immune system attack the cancer, and may interfere with the ability of tumor cells
to grow and spread. Giving ipatasertib in combination with pembrolizumab may be more
effective than pembrolizumab alone in improving some outcomes in patients with
recurrent/metastatic squamous cell cancer of the head and neck.
Stanford Investigators
View full details
-
Study Evaluating Zr-Panitumumab for Assessment of Suspected Metastatic Lesions on 18F-FDG-PET/CT in Head and Neck Squamous Cell Carcinoma
Not Recruiting
More
The purpose of this study is to determine the diagnostic utility of 89Zr-panitumumab to
identify metastatic lesion(s) in subjects with head and neck squamous cell carcinoma (HNSCC).
Stanford is currently not accepting patients for this trial.
For more information, please contact Roan C Raymundo, BS, 650-721-4071.
Stanford Investigators
View full details
-
Nanatinostat Plus Valganciclovir in Patients With Advanced EBV+ Solid Tumors, and in Combination With Pembrolizumab in EBV+ RM-NPC
Not Recruiting
More
This study will evaluate the safety and efficacy of nanatinostat in combination with
valganciclovir in patients with relapsed/refractory EBV-positive solid tumors and in
combination with pembrolizumab in patients with recurrent/metastatic nasopharyngeal carcinoma
Stanford is currently not accepting patients for this trial.
For more information, please contact , .
Stanford Investigators
View full details
-
Study of Magrolimab Combination Therapy in Patients With Head and Neck Squamous Cell Carcinoma
Not Recruiting
More
The goals of this clinical study are to learn about the safety, tolerability, dosing and
effectiveness of the study drug, magrolimab in combination with other anticancer therapies in
patients with head and neck squamous cell carcinoma (HNSCC).
Stanford is currently not accepting patients for this trial.
For more information, please contact Cancer Clinical Trials Office (CCTO), 650-498-7061.
Stanford Investigators
View full details
-
Clinical Trial of a Novel Small Molecule EBNA1 Inhibitor, VK 2019, in Patients With Epstein Barr Virus (EBV)-Positive Nasopharyngeal Cancer (NPC) and Other Epstein-Barr Virus (EBV)-Associated Cancers, With Pharmacokinetic and Pharmacodynamic Correlative Studies
Recruiting
More
To evaluate the anti cancer effect of VK 2019 in subjects with EBV related nasopharyngeal
carcinoma (NPC) for whom there is no other standard treatment available
Lead Sponsor
Stanford Investigators
View full details
-
A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1
Recruiting
More
An open-label, controlled, multi-site, interventional, 2-arm, Phase II trial of BNT113 in
combination with pembrolizumab vs pembrolizumab monotherapy as first line treatment in
patients with unresectable recurrent or metastatic HPV16+ HNSCC expressing programmed cell
death ligand -1 (PD-L1) with combined positive score (CPS) ≥1.
This trial has two parts.
Part A, an initial non-randomized Safety Run-In Phase to confirm the safety and tolerability
at the selected dose range level of BNT113 in combination with pembrolizumab.
Part B, the Randomized part of the trial to generate pivotal efficacy and safety data of
BNT113 in combination with pembrolizumab versus pembrolizumab monotherapy in the first line
setting in patients with unresectable recurrent or metastatic HPV16+ HNSCC expressing PD-L1
with CPS ≥1.
For Part B, an optional pre-screening phase is available for all patients where patients'
tumor samples may be submitted for central HPV16 DNA and central PD-L1 expression testing
prior to screening into the main trial.
Stanford Investigators
View full details
-
Study Evaluating Cemiplimab Alone and Combined With RP1 in Treating Advanced Squamous Skin Cancer
Not Recruiting
More
To estimate the clinical benefit of cemiplimab monotherapy versus cemiplimab in combination
with RP1 for patients with locally advanced or metastatic CSCC, as assessed by overall
response rate (ORR) and complete response rate (CRR) according to blinded independent review.
Stanford is currently not accepting patients for this trial.
For more information, please contact Cancer Clinical Trials Office (CCTO), 650-498-7061.
Stanford Investigators
View full details
-
Phase II Trial of Pembrolizumab in Metastatic or Locally Advanced Anaplastic/Undifferentiated Thyroid Cancer
Recruiting
More
This is a single-arm, open-label trial designed to evaluate the activity of pembrolizumab
therapy in anaplastic thyroid cancer in patients with no curative alternative therapy.
Pembrolizumab (Keytruda-Merck) 200 mg, given IV every 3 weeks, until evidence of progression,
intolerance of treatment, withdrawal of consent or death
Lead Sponsor
Stanford Investigators
View full details
-
A Study of the Safety, Tolerability and Pharmacokinetics of ABBV-368 as a Single Agent and Combination in Subjects With Locally Advanced or Metastatic Solid Tumors
Not Recruiting
More
The primary purpose of this Phase 1, open-label study is to evaluate the safety,
pharmacokinetics, and preliminary efficacy of ABBV-368 as a monotherapy and in combination
with ABBV-181 in participants with locally advanced or metastatic solid tumors. The study
will consist of 3 parts: ABBV-368 dose escalation, ABBV-368 tumor-specific dose expansion
(triple negative breast cancer [TNBC] cohort and head and neck cancer cohort) and 18F-AraG
Imaging Substudy.
Stanford is currently not accepting patients for this trial.
For more information, please contact Cancer Clinical Trials Office (CCTO), 650-498-7061.
Stanford Investigators
View full details
-
Tabelecleucel in Combination With Pembrolizumab in Subjects With Epstein-Barr Virus-associated Nasopharyngeal Carcinoma (EBV+ NPC)
Not Recruiting
More
This is a multicenter, open-label, single-arm Phase 1B/2 study to assess the safety and
efficacy of tabelecleucel in combination with pembrolizumab for the treatment of subjects
with platinum-pretreated, recurrent/metastatic Epstein-Barr Virus-associated Nasopharyngeal
Carcinoma (EBV+ NPC).
Stanford is currently not accepting patients for this trial.
For more information, please contact Cancer Clinical Trials Office (CCTO), 650-498-7061.
Stanford Investigators
View full details
-
A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vascular Endothelial Growth Factor Receptor (VEGFR) -Targeted Therapy
Not Recruiting
More
The objective of this study is to evaluate the effect of cabozantinib compared with placebo
on progression free survival (PFS) and objective response rate (ORR) in subjects with
Radioiodine-Refractory Differentiated Thyroid Cancer (DTC) who have progressed after prior
vascular endothelial growth factor receptor (VEGFR)-Targeted therapy.
Stanford is currently not accepting patients for this trial.
For more information, please contact Cancer Clinical Trials Office (CCTO), 650-498-7061.
Stanford Investigators
View full details
-
Safety and Efficacy of Repeat Administration of Ad/PNP and Fludarabine Phosphate in Patients With Local Head/Neck Cancer
Recruiting
More
Primary Objective: The primary objective of the study is to evaluate the safety of repeat
administration of a dose level of Ad/PNP plus fludarabine phosphate (F-araAMP) which
demonstrated anti-tumor activity in patients with advanced head and neck cancer in a
completed phase I study.
Secondary Objective: The secondary objective is to evaluate the antitumor activity of repeat
administration of Ad/PNP plus F-araAMP.
FDA Office of Orphan Drugs Division is a source of funding for the overall project.
Stanford Investigators
View full details
-
Phase 1/2a Study of VK-2019 in Patients With Epstein-Barr Virus (EBV)-Positive Nasopharyngeal Carcinoma (NPC)
Not Recruiting
More
VK-2019-001 is a 1/2a trial of the oral EBNA-1 targeting agent VK-2019 in patients with
EBV-positive recurrent or metastatic NPC to determine the Maximum Tolerated Dose (MTD) and
Recommended Phase 2 Dose (RP2D), as well as to evaluate the PK profile of VK-2019.
Stanford is currently not accepting patients for this trial.
For more information, please contact Elizabeth Winters, 650-721-6509.
Stanford Investigators
View full details
-
Study of REGN2810 in Patients With Advanced Cutaneous Squamous Cell Carcinoma
Not Recruiting
More
Groups 1 to 4 To estimate the clinical benefit of cemiplimab monotherapy for patients with:
metastatic (nodal or distant) cutaneous squamous cell carcinoma (CSCC), or unresectable
locally advanced CSCC
Group 6 To provide additional efficacy and safety data for cemiplimab monotherapy in patients
with advanced CSCC (metastatic [nodal or distant] or locally advanced treated with cemiplimab
Stanford is currently not accepting patients for this trial.
For more information, please contact Cancer Clinical Trials Office (CCTO), 650-498-7061.
Stanford Investigators
View full details
-
Phase 2 Sequential and Concurrent Chemoradiation for Advanced Nasopharyngeal Carcinoma (NPC)
Not Recruiting
More
This phase 2 trial is studying whether giving a combination of docetaxel, cisplatin, and
fluorouracil chemotherapy followed by the combination of cisplatin with radiation therapy
works in treating patients with advanced nasopharyngeal cancer. Drugs used in chemotherapy,
such as docetaxel, cisplatin, and fluorouracil, work in different ways to stop the growth of
tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy
uses high-energy x-rays to kill tumor cells. Specialized radiation therapy that delivers a
high dose of radiation directly to the tumor may kill more tumor cells and cause less damage
to normal tissue. Giving combination chemotherapy together with radiation therapy may kill
more tumor cells.
Stanford is currently not accepting patients for this trial.
For more information, please contact Risa Jiron, 650-736-1598.
Lead Sponsor
Stanford Investigators
View full details
-
A Phase 1 Dose Escalation Study of OMP-21M18 in Subjects With Solid Tumors
Not Recruiting
More
A phase 1 open-label dose escalation study of OMP-21M18 in subjects with previously treated
solid tumour for which there is no remaining standard curative therapy and no therapy with a
demonstrated survival benefit.
Stanford is currently not accepting patients for this trial.
For more information, please contact Dana Supan, 6507361694.
Stanford Investigators
View full details
-
A 3rd/4th Line Placebo-controlled Trial of Sorafenib in Patients With Predominantly Non Squamous Non-Small Cell Lung Cancer (NSCLC).
Not Recruiting
More
The purpose of the study is to see if sorafenib plus best supportive care (i.e. in addition
to the non-cancer treatments patients would normally receive) is an effective treatment for
lung cancer compared to best supportive care alone. The safety and tolerability of the two
treatment groups will also be compared. The goal of the study is to test the ability of
sorafenib to improve survival compared to best supportive care alone.
Stanford is currently not accepting patients for this trial.
For more information, please contact Melanie San Pedro-Salcedo, 6507241388.
Stanford Investigators
View full details
-
A Study of Vismodegib (GDC-0449) in Patients Treated With Vismodegib in a Previous Genentech-sponsored Phase I or II Cancer Study
Not Recruiting
More
This was a multicenter, open-label extension study. Patients who received vismodegib
(GDC-0449) in a Genentech-sponsored study and who had completed the parent study or who
continued to receive vismodegib at the time the parent study closed were eligible for
continued treatment in this protocol.
Stanford is currently not accepting patients for this trial.
For more information, please contact Shruthi Rangaraj, 6507217159.
Stanford Investigators
View full details
-
A Study of HGS1029 (AEG40826-2HCl) in Subjects With Advanced Solid Tumors
Not Recruiting
More
The purpose of this study is to evaluate the safety and tolerability of HGS1029 in subjects
with advanced solid tumors and to determine a phase 2 dose.
Stanford is currently not accepting patients for this trial.
For more information, please contact Dana Supan, 6507361694.
Stanford Investigators
View full details
-
QUILT-3.026: AMG 655 in Combination With AMG 479 in Advanced, Refractory Solid Tumors
Not Recruiting
More
This is a multi-center, 2-part phase 1b/2 study of AMG 655 in combination with AMG 479 to be
conducted in the United States and Spain.
Part 1 is a dose escalation segment to identify a dose of AMG 655 in combination with AMG 479
that is safe and tolerable.
Part 2 will evaluate the safety and estimate the efficacy of AMG 655 at the dose selected in
Part 1 in combination with AMG 479 for the treatment of patients with advanced NSCLC
(non-squamous histology; squamous histology), CRC, pancreatic cancer, ovarian cancer, and
sarcoma.
Stanford is currently not accepting patients for this trial.
For more information, please contact Dana Supan, 6507361694.
Stanford Investigators
View full details
-
Study of Pembrolizumab (MK-3475) in Adults With Recurrent/Metastatic Cutaneous Squamous Cell Carcinoma (cSCC) or Locally Advanced Unresectable cSCC (MK-3475-629/KEYNOTE-629)
Not Recruiting
More
The purpose of this study is to evaluate the safety and efficacy of pembrolizumab (MK-3475)
in adult participants with recurrent or metastatic(R/M) cutaneous Squamous Cell Carcinoma
(cSCC) or locally advanced (LA) unresectable cSCC that is not amenable to surgery and/or
radiation and/or systemic therapies.
Stanford is currently not accepting patients for this trial.
For more information, please contact Cancer Clinical Trials Office (CCTO), 650-498-7061.
Stanford Investigators
View full details
-
Testing the Addition of an Anti-cancer Immune Therapy Drug (Nivolumab) to the Usual Chemotherapy Treatment (Cisplatin or Carboplatin With Gemcitabine) for Recurrent or Metastatic Nasopharyngeal Cancer
Not Recruiting
More
This phase III trial compares the effect of adding nivolumab to the usual chemotherapy
(cisplatin or carboplatin with gemcitabine) versus standard chemotherapy alone in treating
patients with nasopharyngeal cancer that has come back (recurrent) or spread to other places
in the body (metastatic). Immunotherapy with monoclonal antibodies, such as nivolumab, may
help the body's immune system attack the cancer, and may interfere with the ability of tumor
cells to grow and spread. Chemotherapy drugs, such as cisplatin, carboplatin, and
gemcitabine, work in different ways to stop the growth of tumor cells, either by killing the
cells, by stopping them from dividing, or by stopping them from spreading. Giving nivolumab
with the usual chemotherapy may work better than the standard chemotherapy alone in treating
patients with nasopharyngeal cancer.
Stanford is currently not accepting patients for this trial.
For more information, please contact Site Public Contact, 650-498-7061.
Stanford Investigators
View full details
-
A Dose Escalation and Cohort Expansion Study of Anti-CD27 (Varlilumab) and Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors
Not Recruiting
More
This is a study to determine the clinical benefit (how well the drug works), safety, and
tolerability of combining varlilumab and nivolumab (also known as Opdivo® , BMS-936558). Both
drugs target the immune system and may act to promote anti-cancer effects.
Stanford is currently not accepting patients for this trial.
For more information, please contact Cancer Clinical Trials Office (CCTO), 650-498-7061.
Stanford Investigators
View full details
-
Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Not Recruiting
More
This randomized phase III trial studies chemotherapy to see how well it works with or without
bevacizumab in treating patients with head and neck squamous cell carcinoma that has come
back (recurrent) or that has spread to other parts of the body (metastatic). Drugs used in
chemotherapy, such as docetaxel, cisplatin, carboplatin, and fluorouracil, work in different
ways to stop the growth of tumor cells, either by killing the cells, by stopping them from
dividing, or by stopping them from spreading. Monoclonal antibodies, such as bevacizumab, may
interfere with the ability of tumor cells to grow and spread. Bevacizumab may also make tumor
cells more sensitive to chemotherapy and stop the growth of head and neck cancer by blocking
blood flow to the tumor. It is not yet known whether combination chemotherapy is more
effective when given with or without bevacizumab in treating patients with head and neck
squamous cell carcinoma.
Stanford is currently not accepting patients for this trial.
For more information, please contact Jennifer Wong, 650-723-1002.
Stanford Investigators
View full details
-
A Phase III Trial Evaluating Chemotherapy and Immunotherapy for Advanced Nasopharyngeal Carcinoma (NPC) Patients
Not Recruiting
More
This study is a multi-center, randomized, open label, Phase III clinical trial for advanced
Nasopharyngeal Carcinoma(NPC) Patients.
Drugs used in chemotherapy, such as gemcitabine and carboplatin, work in different ways to
stop the growth of tumor cells, either by killing the cells or by stopping them from
dividing. Giving an infusion of a person's cytotoxic T cells (CTL) that have been treated in
the laboratory may help the body build an effective immune response to kill tumor cells.
Giving combination chemotherapy together with laboratory-treated T cells may kill more tumor
cells. This Phase III trial is to assess if combined gemcitabine-carboplatin (GC) followed by
adoptive T-cell therapy would improve clinical outcome for patients with advanced
nasopharyngeal carcinoma (NPC). It is also the world's first, and largest, Phase 3 T-cell
therapy cancer trial ever conducted, and enrollment is ongoing for 330 patients from 30
hospital centers across Asia and the United States.
This clinical trial is conducted on the back of a successful Phase 2 NPC trial involving 38
patients at the National Cancer Centre, Singapore. This trial produced the best published
2-year (62.9%), and median overall survival (OS) data (29.9 months) in 35 patients with
advanced NPC who received autologous EBV-specific CTL. Kindly see
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3978790/ for the Phase 2 publication titled
"Adoptive T-cell Transfer and Chemotherapy in the First line treatment of Metastatic and/or
Locally Recurrent Nasopharyngeal Carcinoma".
Stanford is currently not accepting patients for this trial.
For more information, please contact Uma R Swathee, 650-721-4079.
Stanford Investigators
View full details
-
Nexavar® Versus Placebo in Locally Advanced/Metastatic RAI-Refractory Differentiated Thyroid Cancer
Not Recruiting
More
Trial of sorafenib versus placebo in the treatment of locally advanced or metastatic
differentiated thyroid cancer refractory to radioiodine
Stanford is currently not accepting patients for this trial.
For more information, please contact Ruth Lira, 6507231367.
Stanford Investigators
View full details
-
Erlotinib in Patients With Resected, Early Stage NSCLC With Confirmed Mutations in the EGFR
Not Recruiting
More
In this research study erlotinib will be given to eligible participants whose lung cancer has
been removed by surgery. Eligible patients have adenocarcinoma, a type of non-small lung
cancer, and must have 1 or more of the following characteristics: be female, be of Asian or
Pacific Rim descent and/or be a never smoker. The potential participant's tumor will be
examined for Epidermal growth factor (EGFR) mutations. EGFR is a protein that is
overexpressed in most non-small cell lung cancers. Some EGFR has been found to have specific
mutations and the participant must have one of these mutations in his tumor.
Erlotinib blocks this protein and may control tumor growth and increase survival. Previous
research has shown that erlotinib is most effective for people who have these specific
mutations in the EGFR.
Stanford is currently not accepting patients for this trial.
For more information, please contact Lei Shura, 650-723-2312.
Stanford Investigators
View full details
-
Study of Nivolumab in Combination With Ipilimumab Compared to the Standard of Care (Extreme Regimen) as First Line Treatment in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Not Recruiting
More
The main purpose of this study is to compare nivolumab and ipilimumab with the extreme
regimen as first line treatment in patients with recurrent or metastatic squamous cell of the
head and neck cancer
Stanford is currently not accepting patients for this trial.
For more information, please contact Cancer Clinical Trials Office (CCTO), 650-498-7061.
Stanford Investigators
View full details
-
A Study of Atezolizumab (an Engineered Anti-Programmed Death-Ligand 1 [PDL1] Antibody) to Evaluate Safety, Tolerability and Pharmacokinetics in Participants With Locally Advanced or Metastatic Solid Tumors
Not Recruiting
More
This Phase I, multicenter, first-in-human, open-label, dose-escalation study will evaluate
the safety, tolerability, and pharmacokinetics of atezolizumab (MPDL3280A) administered as
single agent to participants with locally advanced or metastatic solid malignancies or
hematologic malignancies. The study will be conducted in two cohorts: Dose-escalation cohort
and Expansion cohort.
Stanford is currently not accepting patients for this trial.
For more information, please contact Maria Pitsiouni, 650-721-6977.
Stanford Investigators
View full details
-
A Study of Pharmacokinetic Drug Interaction Study of the Hedgehog Pathway Inhibitor GDC-0449 in Combination With Rosiglitazone or Combined Oral Contraceptive in Patients With Locally Advanced or Metastatic Solid Tumors That Are Refractory to Standard Therapy or for Whom No Standard Therapy Exists
Not Recruiting
More
This is a single-arm, multicenter, Phase Ib study designed to describe the effect of GDC-0449
on the pharmacokinetics of rosiglitazone and oral contraceptives in patients with advanced
solid tumors who are refractory to treatment or for whom no standard therapy exists.
Stanford is currently not accepting patients for this trial.
For more information, please contact Ruth Lira, 6507231367.
Stanford Investigators
View full details
-
A Study of MEHD7945A Versus Cetuximab in Patients With Recurrent/Metastatic Squamous Cell Carcinoma of The Head And Neck
Not Recruiting
More
This phase II, open-label, randomized study will evaluate the efficacy and safety of
MEHD7945A versus cetuximab in patients with recurrent/metastatic squamous cell carcinoma of
the head and neck who have progressed during or following platinum-based chemotherapy.
Patients will be randomized to receive either MEHD7945A 1100 mg intravenously (iv) every 2
weeks or cetuximab 400 mg/m2 iv loading dose followed by 250 mg/m2 iv weekly. Patients
treated with cetuximab (Arm B) may cross-over to MEHD7945A (Arm A) upon central confirmation
of progressive disease and upon meeting eligibility criteria. Anticipated time on study
treatment is until disease progression or intolerable toxicity occurs.
Stanford is currently not accepting patients for this trial.
For more information, please contact Ruth Lira, 6507231367.
Stanford Investigators
View full details
-
Combination Study of Urelumab and Cetuximab in Patients With Advanced/Metastatic Colorectal Cancer or Advanced/Metastatic Head and Neck Cancer
Not Recruiting
More
The purpose of the study is to determine the safety, tolerability and maximum tolerated dose
of Urelumab in combination with Cetuximab in patients with Advanced/Metastatic Colorectal
Cancer or Advanced/Metastatic Squamous Cell Carcinoma of the Head and Neck.
Stanford is currently not accepting patients for this trial.
For more information, please contact Risa Jiron, 650-736-1598.
Stanford Investigators
View full details
-
Study to Assess Safety and Tolerability of AG013 in Oral Mucositis in Subjects Receiving Induction Chemotherapy for the Treatment of Cancers of the Head and Neck
Not Recruiting
More
The purpose of this study is to assess the safety and tolerability of AG013 (genetically
modified L. lactis bacteria engineered to secrete human Trefoil Factor 1), and to explore the
ability of AG013 to attenuate the course and severity of oral mucositis (OM) in subjects
receiving induction chemotherapy for the treatment of head and neck cancer.
Stanford is currently not accepting patients for this trial.
For more information, please contact Ruth Lira, 6507231367.
Stanford Investigators
View full details
-
A Study of ASA404 or Placebo in Combination With Docetaxel in Second-line Treatment for (Stage IIIb/IV) Non-small Cell Lung Cancer
Not Recruiting
More
The purpose of this study is to determine if adding ASA404 to docetaxel chemotherapy makes
the cancer treatment more effective in patients with locally advanced or metastatic non-small
cell lung cancer
Stanford is currently not accepting patients for this trial.
For more information, please contact Melanie San Pedro-Salcedo, 6507241388.
Stanford Investigators
View full details
-
A Phase 2 Study of Amrubicin in Relapsed or Refractory Thymic Malignancies
Not Recruiting
More
A research study of the drug amrubicin in patients with cancer of the thymus (thymoma or
thymic carcinoma). We hope to learn whether this drug is an effective and safe treatment for
thymic cancers.
Stanford is currently not accepting patients for this trial.
For more information, please contact Melanie San Pedro-Salcedo, 650-724-1388.
Stanford Investigators
View full details
-
A Study Evaluating the Efficacy and Safety of Vismodegib (GDC-0449, Hedgehog Pathway Inhibitor) in Patients With Advanced Basal Cell Carcinoma
Not Recruiting
More
This was a Phase II, single-arm, two-cohort multicenter clinical trial evaluating the
efficacy and safety of vismodegib (GDC-0449) in patients with advanced basal cell carcinoma.
All patients received vismodegib until evidence of progression, intolerable toxicities most
probably attributable to vismodegib, or withdrawal from the study.
Stanford is currently not accepting patients for this trial.
For more information, please contact Katherine Connors, 6507217159.
Stanford Investigators
View full details
-
A Study of XL184 (Cabozantinib) With or Without Erlotinib in Adults With Non-Small Cell Lung Cancer
Not Recruiting
More
In Phase 1 of this study, the purpose is to evaluate the safety, tolerability, and highest
safe dose of the multiple receptor tyrosine kinase inhibitor (including VEGFR2, MET, and RET)
XL184 in combination with the EGFR inhibitor erlotinib administered to adults with
Non-Small-Cell Lung Cancer (NSCLC). In Phase 2 of this study, the purpose is to evaluate the
objective response rate of daily oral administration of XL184 with or without erlotinib in
subjects with NSCLC who have progressed after responding to treatment with erlotinib.
Stanford is currently not accepting patients for this trial.
For more information, please contact Lisa Zhou, 6507364112.
Stanford Investigators
View full details
-
A Study of Vismodegib (GDC-0449) in Patients With Locally Advanced or Metastatic Basal Cell Carcinoma
Not Recruiting
More
This is an open-label, non-comparative, multicenter, expanded access study of Vismodegib
(GDC-0449) in patients with locally advanced basal cell carcinoma (BCC) or metastatic BCC
(mBCC) who are otherwise without satisfactory treatment options.
Stanford is currently not accepting patients for this trial.
For more information, please contact Shruthi Rangaraj, 6507217159.
Stanford Investigators
View full details
-
An Investigational Drug, PF-02341066, Is Being Studied In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene
Not Recruiting
More
This is a Phase 2 trial that will evaluate the safety and efficacy of PF-02341066 in patients
with advanced non-small cell lung cancer with a specific gene profile involving the ALK gene.
This trial will also allow patients from a Phase 3 trial who received standard of care
chemotherapy (Study A8081007) to receive PF-02341066.
Stanford is currently not accepting patients for this trial.
For more information, please contact Melanie San Pedro-Salcedo, 6507241388.
Stanford Investigators
View full details
-
Phase 1/1b Study to Evaluate the Safety and Tolerability of Ciforadenant Alone and in Combination With Atezolizumab in Advanced Cancers
Not Recruiting
More
This is a phase 1/1b open-label, multicenter, dose-selection study of ciforadenant, an oral
small molecule targeting the adenosine-A2A receptor on T-lymphocytes and other cells of the
immune system. This trial will study the safety, tolerability, and anti-tumor activity of
ciforadenant as a single agent and in combination with atezolizumab, a PD-L1 inhibitor
against various solid tumors. Ciforadenant blocks adenosine from binding to the A2A receptor.
Adenosine suppresses the anti-tumor activity of T cells and other immune cells.
Stanford is currently not accepting patients for this trial.
For more information, please contact Cancer Clinical Trials Office (CCTO), 650-498-7061.
Stanford Investigators
View full details
-
4D-CT-based Ventilation Imaging for Adaptive Functional Guidance in Radiotherapy
Not Recruiting
More
To develop and investigate a novel radiotherapy technique for preserving lung function based
on a map of lung function.
Stanford is currently not accepting patients for this trial.
For more information, please contact Laura Gable, 650-736-0798.
Stanford Investigators
View full details
-
Biopsy of Human Tumors for Cancer Stem Cell Characterization: a Feasibility Study
Not Recruiting
More
To see if a limited sampling of tumor tissue from human subjects is a feasible way to gather
adequate tissue for cancer stem cell quantification.
Stanford is currently not accepting patients for this trial.
For more information, please contact Ruth Lira, 650-723-1367.
Lead Sponsor
Stanford Investigators
View full details
-
Study of REGN2810 (Anti-PD-1) in Patients With Advanced Malignancies
Not Recruiting
More
This is a phase 1, open-label, multicenter, ascending-dose escalation study of cemiplimab,
alone and in combination with other anti-cancer therapies in patients with advanced
malignancies.
Stanford is currently not accepting patients for this trial.
For more information, please contact Cancer Clinical Trials Office (CCTO), 650-498-7061.
Stanford Investigators
View full details
-
Radiation Therapy With Cisplatin or Cetuximab in Treating Patients With Oropharyngeal Cancer
Not Recruiting
More
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells and shrink tumors.
Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of
tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal
antibodies, such as cetuximab, can block tumor growth in different ways. Some block the
ability of tumor cells to grow and spread. Others find tumor cells and help kill them or
carry tumor-killing substances to them. It is not yet known whether radiation therapy is more
effective with cisplatin or cetuximab in treating oropharyngeal cancer.
PURPOSE: This phase III trial is studying radiation therapy with cisplatin or cetuximab to
see how well it works in treating patients with oropharyngeal cancer.
Stanford is currently not accepting patients for this trial.
For more information, please contact Polly Young, 650-497-7499.
Stanford Investigators
View full details
-
A Phase 1 Study in Patients With HPV16+ Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma
Not Recruiting
More
This is a multi-center, open-label, phase 1 dose escalation and expansion study evaluating
the safety, anti-tumor effect, and immunogenicity of CUE-101 as monotherapy treatment in
second line or CUE-101 Combination Therapy with Pembrolizumab in first line patients with
HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
Stanford is currently not accepting patients for this trial.
For more information, please contact Elizabeth Winters, 650-721-6509.
Stanford Investigators
View full details
-
Radiation Therapy Regimens in Treating Patients With Limited-Stage Small Cell Lung Cancer Receiving Cisplatin and Etoposide
Not Recruiting
More
Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy,
such as etoposide, carboplatin and cisplatin, work in different ways to stop the growth of
tumor cells, either by killing the cells or by stopping them from dividing. It is not yet
known which radiation therapy regimen is more effective when given together with chemotherapy
in treating patients with limited-stage small cell lung cancer. This randomized phase III
trial is comparing different chest radiation therapy regimens to see how well they work in
treating patients with limited-stage small cell lung cancer.
Stanford is currently not accepting patients for this trial.
For more information, please contact Katie Brown, 650-723-1423.
Stanford Investigators
View full details
-
PR104 in Treating Patients With Previously Untreated or Relapsed Small Cell Lung Cancer
Not Recruiting
More
RATIONALE: Drugs used in chemotherapy, such as PR-104, work in different ways to stop the
growth of tumor cells, either by killing the cells or by stopping them from dividing.
PURPOSE: This phase II trial is studying how well PR-104 works in treating patients with
previously untreated or relapsed small cell lung cancer (SCLC).
Stanford is currently not accepting patients for this trial.
For more information, please contact Ruth Lira, 6507231367.
Stanford Investigators
View full details
-
Phase 1 Trial of Oral Ixabepilone
Not Recruiting
More
This Phase 1 study of oral ixabepilone given every 6 hours for 3 doses on Day 1, every 21
days, was a dose-finding study designed to determine the maximum tolerated dose (MTD) and
safety of this dosing schedule in participants with advanced cancer
Stanford is currently not accepting patients for this trial.
For more information, please contact Dana Supan, 6507361694.
Stanford Investigators
View full details
-
Radiation Therapy With or Without Cetuximab in Treating Patients Who Have Undergone Surgery for Locally Advanced Head and Neck Cancer
Not Recruiting
More
RATIONALE: Giving radiation therapy that uses a 3-dimensional (3-D) image of the tumor to
help focus thin beams of radiation directly on the tumor, and giving radiation therapy in
higher doses over a shorter period of time, may kill more tumor cells and have fewer side
effects. Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways.
Some block the ability of tumor cells to grow and spread. Others find tumor cells and help
kill them or carry tumor-killing substances to them. It is not yet known whether radiation
therapy is more effective when given alone or together with cetuximab in treating patients
with head and neck cancer that has been removed by surgery.
PURPOSE: This randomized phase III trial is studying radiation therapy to see how well it
works compared with radiation therapy given together with cetuximab in treating patients who
have undergone surgery for locally advanced head and neck cancer.
Stanford is currently not accepting patients for this trial.
For more information, please contact Alice Banh, 650-723-1423.
Stanford Investigators
View full details
-
Phase I Study of CUDC-101 With Cisplatin and Radiation in Subjects With Head & Neck Cancer
Not Recruiting
More
This is a phase I dose escalation study of CUDC-101 in combination with concurrent cisplatin
and radiation therapy in patients with locally advanced head and neck cancer. CUDC-101 is a
multi-targeted agent designed to inhibit epidermal growth factor receptor (EGFR), human
epidermal growth factor receptor Type 2 (Her2) and histone deacetylase (HDAC). The study is
designed to establish the safety, tolerability and maximum tolerated dose (MTD) of CUDC-101
when administered in combination with concurrent cisplatin and radiation over an 8-week
treatment course, consisting of a one week run-in period of CUDC-101 administered alone,
followed by seven weeks of combination treatment with CUDC-101, cisplatin and radiation
therapy.
Stanford is currently not accepting patients for this trial.
For more information, please contact Ruth Lira, 6507231367.
Stanford Investigators
View full details
-
Study to Evaluate Immunological Response to PD-1 Inhibition in Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Not Recruiting
More
This is a single-center cross-sectional imaging and correlative biomarker study in patients
with Squamous Cell Carcinoma of the Head and Neck (SCCHN). Cohort 1 will be patients with
unresectable or metastatic SCCHN cancer receiving standard of care (SOC) anti-PD-1 treatment
and Cohort 2 will be neoadjuvant study participants who will receive one dose of anti-PD-1
treatment prior to tumor resection or radiation. Blood sampling and tissue biopsies will be
collected from both cohorts and both cohorts will undergo two whole body PET(Positron
Emission Tomography)/CT(Computed Tomography) imaging with [18F]F-AraG. First scan prior to
initiating anti-PD-1 treatment and second scan post initiation of anti-PD-1 treatment in
Cohort 1 and prior to tumor resection or radiation in Cohort 2
Stanford is currently not accepting patients for this trial.
For more information, please contact Stefania U Chirita, 650-723-1423.
Stanford Investigators
View full details
-
Safety Testing of Adding Nivolumab to Chemotherapy in Patients With Intermediate and High-Risk Local-Regionally Advanced Head and Neck Cancer
Not Recruiting
More
This study will evaluate the safety of adding nivolumab to several chemotherapy platforms
with weekly cisplatin, high-dose cisplatin, cetuximab or radiation therapy alone.
Stanford is currently not accepting patients for this trial.
For more information, please contact Cancer Clinical Trials Office (CCTO), 650-498-7061.
Stanford Investigators
View full details
-
Dabrafenib and Trametinib in Treating Patients With BRAF Mutated Ameloblastoma
Not Recruiting
More
This pilot clinical trial studies dabrafenib and trametinib in treating patients with
ameloblastoma and a specific mutation (change) in the BRAF gene. Dabrafenib and trametinib
may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Stanford is currently not accepting patients for this trial.
For more information, please contact Elizabeth Winters, 650-721-6509.
Lead Sponsor
Stanford Investigators
View full details
-
Phase III Trial Of Docetaxel Versus Docetaxel Plus ZD1839 In Head And Neck Cancer
Not Recruiting
More
Drugs used in chemotherapy, such as docetaxel, work in different ways to stop tumor cells
from dividing so they stop growing or die. Gefitinib may stop the growth of tumor cells by
blocking the enzymes necessary for their growth. Combining docetaxel with gefitinib may kill
more tumor cells. It is not yet known whether docetaxel is more effective with or without
gefitinib in treating head and neck cancer. This randomized phase III trial is studying
docetaxel and gefitinib to see how well they work compared to docetaxel alone in treating
patients with metastatic or locally recurrent head and neck cancer.
Stanford is currently not accepting patients for this trial.
For more information, please contact Dimitrios Colevas, 6507249707.
Stanford Investigators
View full details
-
Phase 2 Study of GSK1363089 (Formerly XL880) in Adults With Squamous Cell Cancer of the Head and Neck
Not Recruiting
More
This study is being conducted to determine the best confirmed response rate, safety, and
tolerability of GSK1363089 treatment in adult subjects with squamous cell carcinoma of the
head and neck (SCCHN). GSK1363089 is a new chemical entity that inhibits multiple receptor
tyrosine kinases (RTKs) with growth-promoting and angiogenic properties. The primary targets
of GSK1363089 are the HGF and vascular endothelial growth factor (VEGF) RTK families (eg,
MET, VEGFR2/kinase insert domain receptor [KDR]). Since MET overexpression has been
associated with poorer prognosis and MET tyrosine kinase mutations have been reported in
SCCHN, inhibition of MET receptor and VEGFR2/KDR activation by agents such as GSK1363089 may
be of therapeutic benefit in this patient population.
Stanford is currently not accepting patients for this trial.
For more information, please contact Ruth Lira, 6507231367.
Stanford Investigators
View full details
-
Safety, Tolerability, Pharmacokinetics, and Immunoregulatory Study of Urelumab (BMS-663513) in Subjects With Advanced and/or Metastatic Solid Tumors and Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma
Not Recruiting
More
The purpose of the study is to assess the safety, tolerability, pharmacokinetics and
immunoregulatory activity of urelumab (BMS-663513) in cancer subjects with advanced and/or
metastatic tumors and relapsed/refractory B-Cell Non-Hodgkin's Lymphoma
Stanford is currently not accepting patients for this trial.
For more information, please contact Ami Okada, 650-725-4968.
Stanford Investigators
View full details
-
IRX-2 Regimen in Patients With Newly Diagnosed Stage II, III, or IVA Squamous Cell Carcinoma of the Oral Cavity
Not Recruiting
More
The purpose of this study is to determine whether a pre-operative regimen of the study drug,
IRX-2, a human cell-derived biologic with multiple active cytokine components, plus a single
dose of cyclophosphamide, followed by 21 days of indomethacin, zinc-containing multivitamins,
and omeprazole is active in treatment of oral cavity cancer. The regimen is intended to
stimulate an immune response against the cancer.
Stanford is currently not accepting patients for this trial.
For more information, please contact Priya Hegde, 650-723-0920.
Stanford Investigators
View full details
-
Study for Treatment of Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck or Skin
Not Recruiting
More
This phase 2 study is designed to evaluate the safety and activity of TH-4000, a
hypoxia-activated prodrug in participants with recurrent or metastatic squamous cell
carcinoma of the head and neck or skin.
Stanford is currently not accepting patients for this trial.
For more information, please contact Mary (Tookie) May, 650-721-4079.
Stanford Investigators
View full details
-
Reduced-Dose Intensity-Modulated Radiation Therapy With or Without Cisplatin in Treating Patients With Advanced Oropharyngeal Cancer
Not Recruiting
More
This randomized phase II trial studies the side effects and how well modestly reduced-dose
intensity-modulated radiation therapy (IMRT) with or without cisplatin works in treating
patients with oropharyngeal cancer that has spread to other places in the body (advanced).
Radiation therapy uses high energy x rays to kill tumor cells. Drugs used in chemotherapy,
such as cisplatin, work in different ways to stop the growth of tumor cells, either by
killing the cells, by stopping them from dividing, or by stopping them from spreading. It is
not yet known whether IMRT is more effective with or without cisplatin in treating patients
with oropharyngeal cancer.
Stanford is currently not accepting patients for this trial.
For more information, please contact Polly Young, 650-497-7499.
Stanford Investigators
View full details
-
Modified Dakin's Solution in Reducing Radiation-Induced Dermatitis in Patients With Head and Neck Cancer Undergoing Radiation Therapy
Not Recruiting
More
This randomized phase 3 trial studies how well modified Dakin's solution works in reducing
radiation-induced dermatitis, a common skin reaction to radiation therapy, in patients with
head and neck cancer undergoing radiation therapy. Modified Dakin's solution may reduce
inflammation in the body, which may prevent or reduce dermatitis after radiation therapy.
Radiation therapy in this study is regulatory medical care based on the patient's needs and
the radiation oncologist's judgment. It is not possible nor necessary to explicitly define
the dose or duration of treatment.
Stanford is currently not accepting patients for this trial.
For more information, please contact Amanda Simmons, 650-724-4606.
Lead Sponsor
Stanford Investigators
View full details
-
Radiation Therapy in Treating Patients With Stage I Non-Small Cell Lung Cancer
Not Recruiting
More
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Specialized
radiation therapy that delivers a high dose of radiation directly to the tumor may kill more
tumor cells and cause less damage to normal tissue. It is not yet known which regimen of
stereotactic body radiation therapy is more effective in treating patients with non-small
cell lung cancer.
PURPOSE: This randomized phase II trial is studying the side effects of two radiation therapy
regimens and to see how well they work in treating patients with stage I non-small cell lung
cancer.
Stanford is currently not accepting patients for this trial.
For more information, please contact laura gable, 6507360798.
Stanford Investigators
View full details
-
Study of MEDI4736 Monotherapy and in Combination With Tremelimumab Versus Standard of Care Therapy in Patients With Head and Neck Cancer
Not Recruiting
More
This is a randomized, open-label, multi-center, global, Phase III study to determine the
efficacy and safety of MEDI4736 + tremelimumab combination therapy and MEDI4736 monotherapy
versus SoC therapy in the target patient population.
Stanford is currently not accepting patients for this trial.
For more information, please contact Mary (Tookie) May, 650-721-4079.
Stanford Investigators
View full details
-
Study of Monalizumab and Cetuximab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Not Recruiting
More
The objective of this study is to evaluate in a 3 +3 design, the safety of escalating doses
of Monalizumab given IV in combination with cetuximab in patients who have received prior
systemic regimen(s) for recurrent and/or metastatic squamous cell carcinoma of the head and
neck (SCCHN).
Cohorts expansion will evaluate antitumor activity of monalizumab and cetuximab with or
without anti-PD(L)1
Stanford is currently not accepting patients for this trial.
For more information, please contact Cancer Clinical Trials Office (CCTO), 650-498-7061.
Stanford Investigators
View full details
-
Capecitabine in Treating Patients With Advanced or Recurrent Squamous Cell Carcinoma of the Skin
Not Recruiting
More
Phase 2 evaluation of capecitabine in patients with advanced or recurrent squamous cell
carcinoma of the skin.
Stanford is currently not accepting patients for this trial.
For more information, please contact Ruth Lira, 650-723-1367.
Lead Sponsor
Stanford Investigators
View full details
-
Pilot Study of Sonidegib and Buparlisib in Treating Patients With Advanced or Metastatic Basal Cell Carcinoma
Not Recruiting
More
This pilot trial studies how well sonidegib and buparlisib work in treating patients with
basal cell carcinoma that has spread to other places in the body. Sonidegib and buparlisib
may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Stanford is currently not accepting patients for this trial.
For more information, please contact Anne Lynn Chang, 650-721-7151.
Stanford Investigators
View full details
-
FNA Tumor Sampling for CD137 Modulation: A Pilot Study
Not Recruiting
More
The purpose of this study is to better understand the biology of the body's immune response
to monoclonal antibody therapy for cancer. Your health information will be used to identify
your tissues. The tissue we obtain may be useful for research or education, resulting in new
drugs, therapies or diagnostic procedures.
Stanford is currently not accepting patients for this trial.
For more information, please contact Risa Jiron, 650-736-1598.
Lead Sponsor
Stanford Investigators
View full details
-
Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer
Recruiting
More
This phase II/III trial studies how well radiation therapy works when given together with
cisplatin, docetaxel, cetuximab, and/or atezolizumab after surgery in treating patients with
high-risk stage III-IV head and neck cancer the begins in the thin, flat cells (squamous
cell). Specialized radiation therapy that delivers a high dose of radiation directly to the
tumor may kill more tumor cells and cause less damage to normal tissue. Drugs used in
chemotherapy, such as cisplatin and docetaxel, work in different ways to stop the growth of
tumor cells, either by killing the cells or by stopping them from dividing. Cetuximab is a
monoclonal antibody that may interfere with the ability of tumor cells to grow and spread.
Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune
system attack the cancer, and may interfere with the ability of tumor cells to grow and
spread. The purpose of this study is to compare the usual treatment (radiation therapy with
cisplatin chemotherapy) to using radiation therapy with docetaxel and cetuximab chemotherapy,
and using the usual treatment plus an immunotherapy drug, atezolizumab.
Stanford Investigators
View full details
-
Imaging and Biomarkers of Hypoxia in Solid Tumors
Not Recruiting
More
Hypoxia, meaning a lack of oxygen, has been associated strongly with a wide range of human
cancers. Hypoxia occurs when tumor growth exceeds the ability of blood vessels to supply the
tumor with oxygenated blood. It is currently understood that hypoxic tumors are more
aggressive. Current methods for measuring hypoxia include invasive procedures such as tissue
biopsy, or insertion of an electrode into the tumor. EF5-PET may be a non-invasive way to
measure tumor hypoxia.
Stanford is currently not accepting patients for this trial.
For more information, please contact Justin Carter, 650-725-4796.
Lead Sponsor
Stanford Investigators
- Heather Wakelee
- Quynh-Thu Le, MD
- Edward Graves
- John B. Sunwoo, MD
- Joseph Shrager
- Maximilian Diehn, MD, PhD
- Edward J. Damrose, MD, FACS
- Michael J. Kaplan, MD
- Amato J. Giaccia
- A. Dimitrios Colevas, MD
- Billy W Loo, Jr, MD PhD FASTRO FACR
View full details
-
Oral Rigosertib for Squamous Cell Carcinoma
Not Recruiting
More
The primary objective of this study is to determine if tumors in patients with papillomavirus
(HPV) positive or negative squamous cell carcinoma (SCC) that no longer responds to standard
therapy will decrease in size following treatment with the investigational drug, rigosertib
sodium (ON 01910.Na). A secondary objective is to determine if treatment with rigosertib
causes any side effects.
Rigosertib is an investigational drug, which means that it has not been approved by the U.S.
Food and Drug Administration (FDA) to treat any diseases. We are studying rigosertib as a new
anticancer drug. Tests that we have done in the laboratory suggest that rigosertib works by
blocking cell division in cancer cells and causing them to die.
Stanford is currently not accepting patients for this trial.
For more information, please contact Ruth Lira, 650-723-1367.
Stanford Investigators
View full details
-
Arsenic Trioxide in Treating Patients With Basal Cell Carcinoma
Not Recruiting
More
This pilot clinical trial studies arsenic trioxide in treating patients with basal cell
carcinoma. Drugs used in chemotherapy, such as arsenic trioxide, work in different ways to
stop the growth of tumor cells, either by killing the cells or by stop them from dividing
Stanford is currently not accepting patients for this trial.
For more information, please contact Irene Bailey-Healy, 408-892-7261.
Lead Sponsor
Stanford Investigators
View full details
-
A Study in Advanced Cancer
Not Recruiting
More
The purpose of this study is to find a recommended dose level and schedule of dosing
LY2940680 that can safely be taken by participants with advanced cancer. The study will also
explore the changes in a cancer marker level in skin, hair follicles, buccal cells, and tumor
cells. Finally, the study will help document any antitumor activity this drug may have.
Stanford is currently not accepting patients for this trial.
For more information, please contact Anne Chang, 650-721-7151.
Stanford Investigators
View full details
-
Transoral Surgery Followed By Low-Dose or Standard-Dose Radiation Therapy With or Without Chemotherapy in Treating Patients With HPV Positive Stage III-IVA Oropharyngeal Cancer
Not Recruiting
More
This randomized phase II trial studies how well transoral surgery followed by low-dose or
standard-dose radiation therapy works in treating patients with human papilloma virus (HPV)
positive stage III-IVA oropharyngeal cancer. Radiation therapy uses high-energy x-rays to
kill tumor cells. Drugs used in chemotherapy work in different ways to stop the growth of
tumor cells, either by killing the cells or by stopping them from dividing. Giving radiation
therapy with chemotherapy may kill any tumor cells that remain after surgery. It is not yet
known how much extra treatment needs to be given after surgery.
Stanford is currently not accepting patients for this trial.
For more information, please contact Ekaterina Dib, 650-723-0503.
Stanford Investigators
View full details
-
Individualized Treatment in Treating Patients With Stage II-IVB Nasopharyngeal Cancer Based on EBV DNA
Not Recruiting
More
There are two study questions we are asking in this randomized phase II/III trial based on a
blood biomarker, Epstein Barr virus (EBV) deoxyribonucleic acid (DNA) for locoregionally
advanced non-metastatic nasopharyngeal cancer. All patients will first undergo standard
concurrent chemotherapy and radiation therapy. When this standard treatment is completed, if
there is no detectable EBV DNA in their plasma, then patients are randomized to either
standard adjuvant cisplatin and fluorouracil chemotherapy or observation. If there is still
detectable levels of plasma EBV DNA, patients will be randomized to standard cisplatin and
fluorouracil chemotherapy versus gemcitabine and paclitaxel. Radiation therapy uses high
energy x rays to kill tumor cells. Drugs used in chemotherapy, such as cisplatin,
fluorouracil, gemcitabine hydrochloride, and paclitaxel work in different ways to stop the
growth of tumor cells, either by killing the cells, by stopping them from dividing, or by
stopping them from spreading. It is not yet known whether giving cisplatin and fluorouracil
is more effective than gemcitabine hydrochloride and paclitaxel after radiation therapy in
treating patients with nasopharyngeal cancer.
Stanford is currently not accepting patients for this trial.
For more information, please contact Polly Young, 650-497-7499.
Stanford Investigators
View full details
-
Phase 1 Trial of Hu5F9-G4, a CD47-targeting Antibody
Not Recruiting
More
The purpose of this study is to assess the safety and tolerability of Hu5F9-G4 in
participants with solid tumors.
Stanford is currently not accepting patients for this trial.
For more information, please contact Contact, 650-498-4331.
Stanford Investigators
View full details
-
Pilot LDE225 in Locally Advanced or Metastatic BCC + Previously Tx Non-LDE225 Smoothened Inhibitors
Not Recruiting
More
This is a prospective single-center, open label, pilot study to investigate the safety and
efficacy of LDE225 in patients with locally advanced or metastatic basal cell carcinoma.
Primary Objectives:
• To explore the effects of oral LDE225 on the Progression Free Survival (PFS) of individuals
with locally advanced or metastatic BCC who have been previously treated with a non-LDE225
Smo inhibitor.
Secondary Objectives:
- To evaluate the effect of oral LDE225 on tumor tissue biomarkers of BCC activation (Gii
1, 2, Patched 1,2 and Ki67) in individuals which are non-na"ive to Smo inhibitors other
than LDE225, at baseline and at end-of-treatment
- To describe adverse effects of oral LDE225 in individuals with a history of non-LDE225
Smo inhibitor usage
- To assess the overall survival rates of individuals with locally advanced BCC or
metastatic BCC who have previously taken a non-LDE225 Smo inhibitor after treatment with
LDE225
Stanford is currently not accepting patients for this trial.
For more information, please contact Shruthi Rangaraj, 650-721-7159.
Stanford Investigators
View full details
-
Erlotinib With or Without Hydroxychloroquine in Chemo-Naive Advanced NSCLC and (EGFR) Mutations
Not Recruiting
More
The purpose of this research study is to learn if adding hydroxychloroquine (HCQ) to
erlotinib helps treat non-small cell lung cancer (NSCLC). Another goal of this research study
is to learn more about NSCLC and how it may respond to study treatment. Erlotinib (Tarceva)
is a type of drug called a tyrosine kinase inhibitor (TKI). TKIs block a protein called the
epidermal growth factor receptor (EGFR). EGFR may control tumor growth and tumor cell
survival. However, although TKI drugs can work for some lung cancer patients for a period of
time, eventually the tumor finds a way to resist or counteract the TKI treatment and it
begins to grow again. Hydroxychloroquine (HCQ) is a drug approved by the FDA for treating
malaria, rheumatoid arthritis, and several other diseases. Laboratory research suggests that
when HCQ is given with a TKI, it may help delay or prevent TKI resistance from developing.
Stanford is currently not accepting patients for this trial.
For more information, please contact Zeina Babetty, 6507232983.
Stanford Investigators
View full details
-
Efficacy of XL184 (Cabozantinib) in Advanced Medullary Thyroid Cancer
Not Recruiting
More
The purpose of this research study is to evaluate the progression-free survival (PFS) with
XL184 as compared with placebo (an inactive substance) in subjects with unresectable, locally
advanced, or metastatic medullary thyroid cancer (MTC). Subjects will be randomized to
receive XL184 or placebo in a 2:1 ratio. XL184 is an investigational drug that inhibits
VEGFR2, MET and RET, kinases implicated in tumor formation, growth and migration.
The Clinical Steering Committee for this study, comprised of study doctors who specialize in
medullary thyroid cancer, has provided guidance regarding the design of the study. The
committee includes: Douglas Ball, MD, Barry Nelkin, PhD, Martin Schlumberger, MD and Steven
Sherman, MD.
Stanford is currently not accepting patients for this trial.
For more information, please contact Ruth Lira, 6507231367.
Stanford Investigators
View full details
-
A Study of Aflibercept Administered in Combination With Pemetrexed and Cisplatin in Participants With Advanced Carcinoma
Not Recruiting
More
The purpose of the study was to determine whether the combination of aflibercept, pemetrexed
and cisplatin is safe and effective in treating non-small cell lung cancer (NSCLC).
Stanford is currently not accepting patients for this trial.
For more information, please contact Melanie San Pedro-Salcedo, 6507241388.
Stanford Investigators
View full details
-
An Investigational Drug, PF-02341066 Is Being Studied Versus Standard Of Care In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene
Not Recruiting
More
This is a Phase 3 trial comparing the safety and anti-tumor activity of PF-02341066 versus
pemetrexed or docetaxel in patients with advanced non-small cell lung cancer with specific
gene profile involving the ALK gene after failure of one previous chemotherapy regimen that
included one platinum drug.
Stanford is currently not accepting patients for this trial.
For more information, please contact Melanie San Pedro-Salcedo, 6507241388.
Stanford Investigators
View full details
-
Study of Cabozantinib (XL184) in Adults With Advanced Malignancies
Not Recruiting
More
The purpose of this study is to determine whether or not XL184 demonstrates anti-tumor
activity in selected tumor types under a randomized discontinuation trial (RDT) design.
Subjects who have responded to study drug after 12 weeks of open-label XL184 administration
will continue to take XL184. Subjects who are clearly progressing will discontinue study
treatment and subjects who demonstrate stable disease will be randomized to either XL184 or
placebo. For individual patients, once disease progression is observed, the blind will be
broken and subjects who were randomized to placebo will be offered the option to receive
open-label XL184. Subjects who progressed while taking XL184 will discontinue study
treatment.
Emerging data may support enrollment in an open-label, non-randomized expansion cohort (NRE).
There will be NRE cohorts for prostate and ovarian cancers.
Stanford is currently not accepting patients for this trial.
For more information, please contact Dana Supan, 6507361694.
Stanford Investigators
View full details
-
Erlotinib Plus Tivantinib (ARQ 197) Versus Single Agent Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Not Recruiting
More
The purpose of this study is to evaluate progression-free survival among subjects with KRAS
mutation positive Non-Small Cell Lung Cancer (NSCLC) treated with erlotinib plus tivantinib
(ARQ 197) compared to single agent chemotherapy.
Stanford is currently not accepting patients for this trial.
For more information, please contact Lei Shura, 650-723-2312.
Stanford Investigators
View full details
-
Docetaxel, Cisplatin, and Cetuximab (TPC) in Palliative Treatment of Patients With Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Not Recruiting
More
Docetaxel and cetuximab are FDA-approved for the treatment of squamous cell carcinoma of the
head and neck (SCCHN). Cisplatin and carboplatin, while not FDA-approved for SCCHN, have been
used as standard of care in SCCHN patients in combination with other drugs. This study
evaluates if weekly cisplatin and docetaxel, in combination with cetuximab, is effective in
palliative treatment of patients with SCCHN. These drugs will be given intravenously weekly,
repeated 3 of every 4 weeks until evidence of disease progression or unacceptable adverse
events.
Stanford is currently not accepting patients for this trial.
For more information, please contact Risa Jiron, 650-736-1598.
Lead Sponsor
Stanford Investigators
View full details
-
Study of XL647 in Subjects With NSCLC Who Have Progressed After Responding to Treatment With Gefitinib or Erlotinib
Not Recruiting
More
The purpose of this study is to determine the best confirmed response rate of daily
administration of the multiple receptor tyrosine kinase (RTK) inhibitor (including EGFR and
VEGFR2) XL647 in subjects with NSCLC who have progressed after responding to treatment with
either erlotinib or gefitinib.
Stanford is currently not accepting patients for this trial.
For more information, please contact Lisa Zhou, 6507364112.
Stanford Investigators
View full details
-
A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic Cancers
Not Recruiting
More
This is a study of CDX-1127, a therapy that targets the immune system and may act to promote
anti-cancer effects. The study enrolls patients with hematologic cancers (certain leukemias
and lymphomas), as well as patients with select types of solid tumors.
Stanford is currently not accepting patients for this trial.
For more information, please contact Jennifer Vargas, 650-723-0371.
Stanford Investigators
View full details
-
Clinical Study of BYM338 for the Treatment of Unintentional Weight Loss in Patients With Cancer of the Lung or the Pancreas
Not Recruiting
More
A safety & efficacy clinical study of the investigational medicinal product BYM338 for the
treatment of unintentional weight loss in patients with cancer of the lung or the pancreas
Stanford is currently not accepting patients for this trial.
For more information, please contact Melanie San Pedro-Salcedo, 6507241388.
Stanford Investigators
View full details
-
Talactoferrin in Treating Patients With Relapsed or Refractory Non-Small Cell Lung Cancer or Squamous Cell Head and Neck Cancer
Not Recruiting
More
This phase I trial studies how well talactoferrin works in treating patients with relapsed or
refractory non-small cell lung cancer (NSCLC) or squamous cell head and neck cancer.
Biological therapies, such as talactoferrin, may stimulate the immune system in different
ways and stop tumor cells from growing
Stanford is currently not accepting patients for this trial.
For more information, please contact Melanie San Pedro-Salcedo, 6507241388.
Lead Sponsor
Stanford Investigators
View full details
-
Metabolic Reprogramming Therapy for Treatment of Recurrent Head and Neck Cancers
Not Recruiting
More
The purpose of this study is to study the effect of the drug DCA (dichloroacetate) on
recurrent head and neck cancers. Part of this study will also use EF5 PET scan to study tumor
hypoxia.
Stanford is currently not accepting patients for this trial.
For more information, please contact Alice Banh, 650-723-1423.
Stanford Investigators
View full details
-
Trial of Nivolumab vs Therapy of Investigator's Choice in Recurrent or Metastatic Head and Neck Carcinoma (CheckMate 141)
Not Recruiting
More
The purpose of this study is to find out whether Nivolumab will significantly improve overall
survival as compared to therapy of investigator's choice in patients with recurrent or
metastatic head and neck carcinoma.
Stanford is currently not accepting patients for this trial.
For more information, please contact Risa Jiron, 650-736-1598.
Stanford Investigators
View full details
-
BIBW 2992 (Afatinib) in Head & Neck Cancer
Not Recruiting
More
The primary objective of this study is to explore the efficacy of BIBW 2992 compared with
cetuximab (Erbitux) in patients with metastatic or recurrent head and neck cancer after
failure of platinum-containing therapy. In addition, the trial aims to clarify the influence
of EGFR genotype on tumor response to the treatment regimens.
Stanford is currently not accepting patients for this trial.
For more information, please contact Ruth Lira, 6507231367.
Stanford Investigators
View full details
-
Study of XL184 (Cabozantinib) in Adults With Advanced Malignancies
Not Recruiting
More
The purpose of this study is to determine the best and safest dose of XL184 administered
orally. XL184 is a new chemical entity that inhibits VEGFR2, MET and RET, kinases implicated
in tumor formation, growth and migration. To determine the highest safe dose, subjects will
receive different amounts of the drug. The first group of subjects will receive the lowest
dose of XL184. As long as no medically unacceptable side effects are noted, the dose will be
increased for the next group. When the maximum tolerated dose (MTD) is reached, at least 20
subjects with Medullary Thyroid Cancer (MTC) will be enrolled to evaluate the effect of XL184
in this population.
Stanford is currently not accepting patients for this trial.
For more information, please contact Ruth Lira, 6507231367.
Stanford Investigators
View full details
-
Lapatinib and Radiation for Stage III-IV Head and Neck Cancer Patients Who Cannot Tolerate Concurrent Chemotherapy
Not Recruiting
More
We propose to combine lapatinib with RT alone in patients with locally advanced head and neck
cancer who cannot tolerate chemotherapy. The main objective of the study is to determine the
efficacy of combining concurrent radiation and lapatinib in terms of time-to-progression
(TTP) in this group of patients. In addition, we will determine the 2-year locoregional
control rate (LRC), progression-free survival (PFS) and overall survival (OS) in these
patients. We will also evaluate the profile and frequency of late toxicity, specifically
mucosal and dermatologic toxicity, of the combination of lapatinib and RT in patients with
locally advanced head and neck squamous cell carcinoma (HNSCC).
Stanford is currently not accepting patients for this trial.
For more information, please contact Brian Khong, 6507254777.
Stanford Investigators
View full details
-
Induction Chemotherapy Followed By Cetuximab and Radiation in HPV-Associated Resectable Stage III/IV Oropharynx Cancer
Not Recruiting
More
RATIONALE: Drugs used in chemotherapy, such as paclitaxel and cisplatin, work in different
ways to stop the growth of tumor cells, either by killing the cells or by stopping them from
dividing. Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways.
Some block the ability of tumor cells to grow and spread. Others find tumor cells and help
kill them or carry tumor-killing substances to them. Radiation therapy uses high energy
x-rays to kill tumor cells. Giving paclitaxel, cisplatin, and cetuximab together with
radiation therapy may kill more tumor cells.
PURPOSE: This phase II trial is studying paclitaxel, cisplatin, and cetuximab to see how well
they work when followed by cetuximab and two different doses of intensity-modulated radiation
therapy in treating patients with HPV-associated stage III or stage IV cancer of the
oropharynx that can be removed by surgery.
Stanford is currently not accepting patients for this trial.
For more information, please contact Lauren Pernicka, 6507216977.
Stanford Investigators
View full details
-
An Observational Study of the Ethnic Impact of Patients Undergoing Second (2nd) Line Treatment for Non-Small Cell Lung Cancer Using Pemetrexed
Not Recruiting
More
This large, non-randomized observational study is being conducted to provide data about the
impact of ethnic origin on outcomes and resource utilization during the 2nd line treatment of
non-small cell lung cancer (NSCLC) in a routine medical care setting.
Stanford is currently not accepting patients for this trial.
For more information, please contact Lisa Zhou, 6507364112.
Stanford Investigators
View full details
